Utomilumab, previously known as PF-2566, represents a noteworthy therapeutic avenue in autoimmune disease . This engineered antibody specifically inhibits the activation of the – a key molecule implicated in complement-mediated immunological cytotoxicity . Current findings indicates promising eff